Arterial hypertension related to sunitinib

Apply

Arterial hypertension related to sunitinib

Journal Title: OncoReview - Year 2011, Vol 1, Issue 3

Abstract

Hypertension is a common concomitant disease in patients with renal carcinoma and a frequent complication of sunitinib therapy. Blocking of VEGF-dependent pathway leads to endothelial dysfunction, reduced nitric oxide production and reduced microvascular density. Clinically, this results in increased peripheral vascular resistance and consequently increase in blood pressure. The diagnosis of iatrogenic arterial hypertension should be in accordance with the guidelines of the European Society of Hypertension and the Polish Society of Hypertension. Home blood pressure measurements are very useful but 24-hour ambulatory blood pressure monitoring is necessary in some cases. Early diagnosis of iatrogenic hypertension gives opportunity to apply the optimal antihypertensive treatment and to prevent cardiotoxicity. When choosing antihypertensive agents it is important to be awared of coexisting diseases, these drugs should not interact with sunitinib. Hypertension related to sunitinib is the positive predictive factor of anticancer therapy and that is why sunitinib discontinuation due to hypertension should be very rare.

Authors and Affiliations

Sebastian Szmit, Krzysztof Filipiak, Magdalena Zaborowska, Agnieszka Gębara-Puchniarz, Cezary Szczylik

Keywords

jatrogenne nadciśnienie tętnicze czynnik predykcyjny Leczenie hipotensyjne kardiotoksyczność terapia antyangiogenna sunitinib iatrogenic arterial hypertension antiangiogenic therapy

EP ID EP53114
DOI -
Views 249
Downloads 0